Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19+CD22 CAR T-cells for High Risk/Relapsed Paediatric ALL
NCT02443831Phase 1Recruiting
- Sponsor
- University College London
- Start
- Apr 2016
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19/22 CAR T cells in acute lymphoblastic leukemia (ALL), sponsored by University College London. Primary endpoints: Incidence of unacceptable toxicity following CD19+CD22 CAR T-cell infusion at 28 days and Molecular remission at 28 days. Started Apr 2016; status: recruiting.
02
Drugs
anti-CD19/22 CAR T cells
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02443831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02443831.